The susceptibilities of 40 strains of various Mycoplasma species to 10 classes of antimicrobial agents were compared in vitro by a broth microdilution method. The strains tested comprised 20 strains of four AIDS-associated species -M. penetrans (1 strain), M. fermentas (5 strains), M. pirum (6 strains) and M. genitalium (8 strains) -nine strains of the urogenital tract species M. hominis and 11 strains of M. pneumoniae. The results demonstrated wide variation in the susceptibilities of the different Mycoplasma spp. to different classes of antimicrobial agent. All the mycoplasmas were susceptible or highly susceptible to the fluoroquinolones, with sparfloxacin the most active, and to the diterpine antibiotic tiamulin. M. pneumoniae and M. genitnlium strains were also highly susceptible to the macrolides, particularly azithromycin and had similar antibiotic susceptibility patterns to most other antimicrobial agents. However, all strains of M. genitalium were resistant to streptomycin (MIC 250->500 mg/L) whereas all M. pneumoniae isolates, except the MAC strain, were susceptible (MICs 1.25-12.5 mg/L). M. pirum isolates varied considerably in their susceptibility to macrolides (MIC range versus azithromycin 0.0025-> 100 mg/L). M. .fermentarts strains were susceptible to the tetracyclines, lincosamides and mupirocin, but varied in susceptibility to aminoglycosides. Most M. hominis strains were susceptible to the tetracyclines and all were susceptible to clindamycin and mupirocin. M penetrans GTU 54 was susceptible to azithromycin, the tetracyclines and lincosamides as well as to the fluoroquinolones and tiamulin.
Introduction
Over the past decade various species of Mycoplasma have been cultured from or detected in body fluids or tissues from AIDS patients or HIV-seropositive individuals. Strains of M. fermentans, M. penetrans and M. pirum have all been cultured during such studies [l-61 and M. genitalium has been detected by the polymerase chain reaction [ 51, leading to speculation that they might act as co-factors in the pathogenesis of AIDS.
The highly fastidious urogenital tract species M. genitalium has also been isolated in culture from the throats of non-AIDS patients in association with M. pneumoniae [7] , although it is unclear whether M. genitalium plays any role in respiratory disease. However, as M. genitalium and M. pneumoniae share many properties -including the presence of an organised tip attachment structure, similar biochemical characteristics, adherence capabilities and serological cross-reactivities -differentiation in the clinical laboratory is difficult [8, 91. Attempts to detect antibiotics with selective activity against one or other of these species, which could aid in their differentiation, have so far been unsuccessful [8] .
The potential importance of mycoplasmas in AIDS, their role in other human infections and their involvement as cell-culture contaminants has led to studies of the antimicrobial susceptibilities of some of these species [8, . This report extends those investigations, compares the antimicrobial susceptibilities of M. genitalium and M. pneumoniae strains and Six recent isolates of M. hominis (M443/90, M411/ 90, M286/93, M329/92, M265/92 and M680/90) from infected hospitalised patients in the UK, and strain H27 isolated from the urethra of a male with acute Reiter's syndrome in 1962 were supplied by Dr D. Pitcher (Central Public Health Laboratory, 6 1 Colindale Avenue, London). Dr J. Fabbri (Kantonsspital, Basel, Switzerland) supplied M. hominis strain Basel isolated from a Swiss patient with pneumonia. Five previously documented strains of M. pirum isolated from PBMCs from AIDS patients (COL, BER, RAO, VUC and NOU) [5] were supplied by Dr 0. Grau (Institute Pasteur) and strain ICRF (UK cell culture isolate) by Helena M. Windsor (Mycoplasma Experience Ltd, Reigate, Surrey). These strains were tested against a wide selection of antimicrobial agents. Dr J. G. Tully (Mycoplasma Section, NIAID, Frederick Cancer Research Facility, Frederick, MD, USA) provided four additional American (1 90 1672, 1890758, 1902677 and FD870) and one British (MAD-T) lyophilised cell-culture isolates of M. pirum, identified and described previously [26] . These strains were used only to confirm the macrolide susceptibilities of M. pirum cell-culture isolates. [29] with species-specific antisera. Antisera to M. genitalium G37 inhibited the reference strain and all the donated M. genitalium strains, but showed some cross-reaction with M. pneumoniae strains FH and 1428. M. penetrans GTU 54, for which no growth inhibiting antiserum was available, was used within three in-vitro passages after recovery from the freeze-dried state. All strains were cultured on inhibit or-free mycoplasmal agar and were found to be free from bacterial contamination. Growth of the glucose-fermenting mycoplasmas was denoted by a change in colour of the medium from pink to orange/yellow and that of M. hominis from orange/yellow to pink.
Mycoplasma culture media

Preparation of stock cultures
All mycoplasma strains were grown aerobically at 36°C in mycoplasma broth in sterile plasitc 5-ml screw-capped vials until an acid or alkaline colour shift occurred. After addition of sterile glycerol 5% w/v the cultures were dispensed in 1-ml aliquots and frozen at -70°C. These were used to initiate further broth cultures, which, after the addition of 4 ml of fresh broth medium and incubation until a definite colour change occurred, were titrated in sealed microdilution trays to determine the number of colour changing units (ccu) after a recorded period of incubation. Replication of this procedure allowed the preparation of inocula which were then further diluted in mycoplasma broth to give between lo3 and lo5 ccu/ml for use in MIC tests.
Sources and preparation of antimicrobial agents
With the exception of the following, all compounds were supplied by Sigma. Sparfloxacin (technical grade) and azithromycin (technical grade) were supplied by Rhbne Poulenc Rorer, Paris, France and Pfizer Central Research, Sandwich, Kent, respectively. Tiamulin hydrogen fumarate was supplied by Sandoz, and mupirocin lithium salt and clarithromycin by Smith Kline Beecham. Sterile solutions of ciprofloxacin (Ciproxin, Bayer) and netilmicin (Netillin, ScheringPlough) were purchased and diluted for use in MIC tests. Most of the compounds were dissolved in deionised water to achieve a concentration of 1 mg/ml and were sterilised by membrane filtration (0.2 pm pore size). The aminoglycosides were prepared at a concentration of 4 mg/ml. Erythromycin, clarithromycin and aztithromycin were dissolved in aqueous ethanol 10% v/v. Ofloxacin and sparfloxacin were first dissolved in sterile 0.1 NNaOH and were then made up to volume with de-ionised water before sterilisation. Further compound dilutions were prepared in sterile plastic or glass vials at double the required concentration in mycoplasma broth to allow for a 1: 1 dilution by the mycoplasma inoculum in MIC tests.
The dilution series of antimicrobial agents used included both 10-fold and doubling dilutions to minimise dilution errors and to reduce excessive compound 'carry over'. The dilution ranges used to test particular mycoplasma-antimicrobial combinations varied and were selected either with prior knowledge of the likely MIC or after siting experiments. Thus, M. .fermentans strains, some of which have been shown previously to be resistant to aminoglycosides [I I], were tested against a range of concentrations for this class of compound from 500 to 0.25 mg/L, whereas M. pneumoniae strains, which are known to be highly sensistive to macrolides [8] , were tested against a much lower range, e.g., 1-0.0001 mg/L, as were the &I. genitalium strains. Other dilution ranges used for various mycoplasmal-antimicrobial combinations were 100-0.1 mg/L and 10-0.01 mg/L.
MIC tests
MIC tests were performed in 96-well, microdilution sensititre plates by a modification of the method described by Tanner and Wu [30] . The compound dilutions were mixed with an equal volume (100 pl) of the challenge inocula containing 1 O3 -1 O5 ccu/ml in microtitration wells. Each sensititre plate contained uninoculated medium as a sterility control, medium at pH 6.8 or pH 7.6 as end-point controls (depending on whether the pH shift was to an acid or alkaline reaction) and drug-free inoculated growth controls. To confirm the challenge inoculum titres, 100 pl of dilutions of the challenge inoculum (1 0' -10') were added to 100 pl of medium in sensititre wells. The plates were then sealed with adhesive film (Falcon) and were incubated at 36°C until the colour in the growth control well matched that of the end-point control. The incubation periods varied according to the Mycoplasma species, the faster growing species taking 2-3 days to cause a colour change and the slower growers such as M. genitalium up to 7 days. Initial MICs were recorded when the colour of the growth control matched that of the end-point control, the MIC being the lowest drug concentration to show no change in colour. Final MICs were recorded 7 days later and were the lowest drug concentration in which no colour change was seen. Incubation of the plates containing dilutions of the challenge inocula was continued until colour changes were complete. If MIC end-points were not achieved, or if the mycoplasma challenge fell outside lo3-lo5 ccu/ml, tests were repeated.
Results
The in-vitro susceptibilities of the six mycoplasma species examined to 10 classes of antimicrobial agents are shown in The current results clearly demonstrate the wide variation in susceptibilities of AIDS-associated and human urogenital tract and respiratory mycoplasmas to different classes of antibiotic. Sparfloxacin had excellent in-vitro activity against all the Mycoplasma spp. tested and, therefore, has significant potential for treating mycoplasma infections in AIDS patients and infections caused by urogenital tract mycoplasmas and M. pneumoniae in non-AIDS patients. Tiamulin also had a broad spectrum of good anti-mycoplasmal activity in vitro, but is not licensed for human use. However, both these compounds might offer alternative means of eradicating human mycoplasmas from tissue culture cells if used under controlled conditions. Ciprofloxacin has already been recommended for this purpose [32] .
The excellent in-vitro anti-mycoplasmal activities recorded here for the macrolides, particularly azithro- The complete resistance of the AIDS-associated M. fermentans strain incognitus and M. fermentans cell culture isolates to aminoglycosides and the aminoglycoside susceptibility of M. fermentans strains isolated from patients without the use of eukaryotic cells has been reported previously [ 1 1,381. This has been used as an argument for concluding that the incognitus strain was probably a cell culture contaminant. The current observation that M. fermentans AOU, isolated from PBMCs purified from the blood of an AIDS patient, was also aminoglycoside-resistant, while strains 5 and 29, recovered from the urine of AIDS patients in cell-free medium, were aminoglycosidesensitive, suggests that strain AOU also probably originated from cultured cells rather than from the AIDS patient. This suggestion is supported by a recent observation that the AOU strain is closely related to a Japanese mouse cell culture isolate (F-7) when compared by the newly developed pyrolysis mass spectrometry method for M. fermentans [39] .
